Swiss Wearable Brand MyKronoz Announces Availability of ZeTime, The World’s First Hybrid Smartwatch with Mechanical Hands over Color Touchscreen
Following a historic crowdfunding campaign raising more than $6 million, MyKronoz, the premier watchmaking brand for the smart generation, today announced the debut of its ZeTime hybrid smartwatch at IFA 2017. The device will be on display and available for demos at IFA September 1-6 in Berlin and for the first time ever in the United States at MWC Americas September 12-14 in San Francisco. Global availability and ship dates have also been announced, with both slated to begin in September.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170830005837/en/
ZeTime MyKronoz (Photo: Business Wire)
The world's first hybrid smartwatch with mechanical hands over a TFT color touchscreen, ZeTime blends the classic design of a traditional Swiss timepiece with the most advanced features of a smartwatch. MyKronoz’s proprietary ‘Smart Movement’ technology enables ZeTime’s always-on hands to function for up to 30 days with a single charge, ensuring the primary function of the watch – to tell time – is always running. The hybrid device is available in size Regular (44mm) and Petite (39mm) and is priced starting at $199.90, making it both aesthetically pleasing and affordable for all.
Being a true crossover wearable with no compromises, ZeTime is a demonstration of the MyKronoz company vision. “ZeTime has already made history thanks to the support of over 30,000 backers, becoming the most-funded hybrid smartwatch and the largest campaign ever from a European company. With this launch, we are not only reimagining the experience consumers have with technology. Most importantly, we are creating a new standard in both wearable and traditional watchmaking industries. This marks a turning point for our company, and shows our commitment to become tomorrow’s leader in this new generation of connected watches,” says Boris Brault, MyKronoz CEO.
With ZeTime, users can control their phone’s functions right from their wrist: view incoming calls, read social networking notifications, check weather forecasts, play music, take a photo, and more. The hybrid smartwatch is also equipped with a 3-axis accelerometer and optical heart-rate sensor to track activity by monitoring heart-rate, steps, distance, calories, active minutes and sleep. ZeTime will also alert users to extended periods of inactivity to encourage them to be more active. Additionally, the device is water resistant to 5 ATM.
Created to fit all styles, ZeTime’s elegant aesthetic features a sleek stainless steel watch case, sapphire glass, and a variety of interchangeable digital watch faces and bands including silicon, genuine leather, carbon-fiber and more. ZeTime seamlessly connects via Bluetooth with both Android and iOS phones (Android 5.0+ or iOS 8.0 and above).
For additional product information and where to buy, please visit https://www.mykronoz.com/us/en/press/.
MyKronoz at IFA
September 1-6 in Berlin
iZone Hall 15.1, booth 182
MyKronoz will attend Showstoppers @ IFA 2017 on Thursday, August 31, 2017, 6:00 to 9:00 p.m. at South Entrance Hall, Messe Berlin Fairgrounds in Berlin, Germany
MyKronoz at MWC Americas
September 12-14 in San Francisco
North Hall Stand N. 1166
MyKronoz will attend Pepcom MobileFocus® America on Monday, September 11, 6:00 to 9:00 p.m. at Metreon City View, 135 4th Street, 4th Floor in San Francisco, California
Founded in January 2013, MyKronoz is a Swiss company based in Geneva that designs and develops wearable devices intended to improve increasingly mobile, connected and digital lifestyles. MyKronoz strives to expand and facilitate the mobile-user experience with stylish, intuitive and functional techcessories. Now present in 40 countries, carried by major retailers and partners worldwide: Orange, Auchan, Carrefour, Best Buy, Walmart, Yodobashi, HMV, MyKronoz offers a full range of connected devices spanning across four product categories: activity trackers, smartwatches, hybrid smartwatches and watch phones. With a unique DNA mixing mobile tech and fashion, MyKronoz’s goal is to cater to the needs and tastes of the world’s most various user types thanks to a full iOS, Android and Windows Phone compatibility at an affordable price. For more information, visit www.mykronoz.com or follow @mykronoz on Twitter.
Spark for MyKronoz
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers17.2.2018 21:00 | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 08:00 | Pressemelding
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 18:26 | Pressemelding
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 17:05 | Pressemelding
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 09:03 | Pressemelding
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 08:00 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and